Fiche centre
Pharmasite Research, Inc.
Baltimore — United States
Essais liés6clinical trials
VilleBaltimorelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04396574
Essais cliniques associés
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Lasmiditan | Migraine | Phase 3 | NCT04396236 | PIONEER-PEDS1 — A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | TERMINATED |
| Atogepant | Migraine | Phase 3 | NCT03777059 | 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine | COMPLETED |
| Atogepant | Migraine | Phase 3 | NCT03939312 | Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine | COMPLETED |
| Galcanezumab | Migraine | Phase 3 | NCT04616326 | REBUILD-2 — A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine | ACTIVE_NOT_RECRUITING |
| Lasmiditan | Migraine | Phase 3 | NCT04396574 | PIONEER-PEDS2 — A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | TERMINATED |
| Galcanezumab | Migraine | Phase 3 | NCT03432286 | REBUILD-1 — A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine | ACTIVE_NOT_RECRUITING |